CENTESSA PHARMACEUTICALS PLC CNTA 深 沪
等待开盘 12-20 09:30:00 美东时间
24.87
+0.020
+0.08%
华盛通- 最 高25.28
- 今 开24.89
- 成交量 68.59万股
- 最 低 24.17
- 昨 收 24.85
- 总市值 33.33亿
- 52周最高 30.58
- 市盈率 静 --
- 换手率 0.51%
- 52周最低 9.60
- 委 比 -1.06%
- 总股本 1.34亿
- 历史最高 30.58
- 量 比 0.44
- 振 幅 4.47%
- 历史最低 2.885
- 每 手 1
- 风险率 4.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Oppenheimer Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $62
Oppenheimer analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and raises the price target from $40 to $62.
12-11 00:36
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
B. Riley Securities Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $42
B. Riley Securities analyst Mayank Mamtani maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and raises the price target from $33 to $42.
12-01 23:06
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $43
Guggenheim analyst Debjit Chattopadhyay maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and raises the price target from $28 to $43.
11-18 22:51
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
美股牛股 | BBAI涨超18%，分析师称收购Ask Sage将为2026年收入提供强劲助力；昂跑涨18%
BBAI涨超18%，分析师称收购Ask Sage将为2026年收入提供强劲助力；ONON涨18%，Q3净销售额7.94亿瑞士法郎高于预期，上调年度收入展望>>
11-13 14:54
Centessa Pharmaceuticals prices $250M offering at $21.5 per ADS
Clinical-stage pharmaceutical company Centessa Pharmaceuticals (CNTA) priced an underwritten public offering of ~11.63M ADSs, each representing one ordinary share, at a price to the public of $21.50...
11-12 16:22
Centessa Pharmaceuticals announces proposed public offering
Centessa Pharmaceuticals (NASDAQ:CNTA) announced on Tuesday that it has started an underwritten public offering of American Depositary Shares (ADS), each representing one ordinary share. The company ...
11-12 05:08
